---
title: "NVCR.US (NVCR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NVCR.US/news.md"
symbol: "NVCR.US"
name: "NVCR.US"
parent: "https://longbridge.com/en/quote/NVCR.US.md"
datetime: "2026-05-21T20:59:58.291Z"
locales:
  - [en](https://longbridge.com/en/quote/NVCR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVCR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVCR.US/news.md)
---

# NVCR.US (NVCR.US) — Related News

### [NovoCure (NVCR) Is Up 9.7% After Raising 2026 Revenue Outlook And Posting Stronger Q1 Sales](https://longbridge.com/en/news/286397038.md)
*2026-05-14T10:13:06.000Z*
> NovoCure (NVCR) shares rose 9.7% following the company's Q1 2026 results, which reported sales of $174.06 million and a 

### [3 Overlooked Stocks Set to Soar in 2026](https://longbridge.com/en/news/285214574.md)
*2026-05-05T13:15:25.000Z*
> Three overlooked biotech stocks, Axsome Therapeutics, NovoCure Limited, and MBX Biosciences, are poised for growth by 20

### [Stocks with rising relative price strength: Novocure](https://longbridge.com/en/news/285088203.md)
*2026-05-04T14:41:18.000Z*
> Novocure sees its Relative Strength Rating enter the 80-plus level.

### [NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook](https://longbridge.com/en/news/284962907.md)
*2026-05-02T09:56:48.000Z*
> NovoCure (NasdaqGS:NVCR) has received FDA approval for Optune Pax for locally advanced pancreatic cancer, marking its U.

### [](https://longbridge.com/en/news/284944635.md)
*2026-05-01T22:02:13.000Z*
> The Nasdaq Biotechnology Index fell 1.09%. Among its constituents, Summit Therapeutics Plc dropped 24.91%, Syndax Pharma

### [](https://longbridge.com/en/news/284789186.md)
*2026-04-30T13:26:58.000Z*
> NovoCure shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY26 

### [NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/284779367.md)
*2026-04-30T13:09:32.000Z*
> NovoCure (NASDAQ:NVCR) reported strong Q1 2026 results, highlighting double-digit growth in active patients and net reve

### [Novocure | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 174.06 M](https://longbridge.com/en/news/284753306.md)
*2026-04-30T11:03:50.000Z*